276 related articles for article (PubMed ID: 2155181)
1. Comparison of the glycolipid receptor specificities of Shiga-like toxin type II and Shiga-like toxin type II variants.
Samuel JE; Perera LP; Ward S; O'Brien AD; Ginsburg V; Krivan HC
Infect Immun; 1990 Mar; 58(3):611-8. PubMed ID: 2155181
[TBL] [Abstract][Full Text] [Related]
2. One step high yield affinity purification of shiga-like toxin II variants and quantitation using enzyme linked immunosorbent assays.
Acheson DW; Jacewicz M; Kane AV; Donohue-Rolfe A; Keusch GT
Microb Pathog; 1993 Jan; 14(1):57-66. PubMed ID: 8321118
[TBL] [Abstract][Full Text] [Related]
3. The specific activities of Shiga-like toxin type II (SLT-II) and SLT-II-related toxins of enterohemorrhagic Escherichia coli differ when measured by Vero cell cytotoxicity but not by mouse lethality.
Lindgren SW; Samuel JE; Schmitt CK; O'Brien AD
Infect Immun; 1994 Feb; 62(2):623-31. PubMed ID: 8300218
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the role of Shiga and Shiga-like toxins in mediating direct damage to human vascular endothelial cells.
Tesh VL; Samuel JE; Perera LP; Sharefkin JB; O'Brien AD
J Infect Dis; 1991 Aug; 164(2):344-52. PubMed ID: 1649877
[TBL] [Abstract][Full Text] [Related]
5. Investigation of Shiga-like toxin binding to chemically synthesized oligosaccharide sequences.
Armstrong GD; Fodor E; Vanmaele R
J Infect Dis; 1991 Dec; 164(6):1160-7. PubMed ID: 1659599
[TBL] [Abstract][Full Text] [Related]
6. Escherichia coli cytotoxins and enterotoxins.
Gyles CL
Can J Microbiol; 1992 Jul; 38(7):734-46. PubMed ID: 1393838
[TBL] [Abstract][Full Text] [Related]
7. Glycoconjugate receptors for P-fimbriated Escherichia coli in the mouse. An animal model of urinary tract infection.
Lanne B; Olsson BM; Jovall PA; Angström J; Linder H; Marklund BI; Bergström J; Karlsson KA
J Biol Chem; 1995 Apr; 270(15):9017-25. PubMed ID: 7721812
[TBL] [Abstract][Full Text] [Related]
8. Globotetraosylceramide is recognized by the pig edema disease toxin.
DeGrandis S; Law H; Brunton J; Gyles C; Lingwood CA
J Biol Chem; 1989 Jul; 264(21):12520-5. PubMed ID: 2663859
[TBL] [Abstract][Full Text] [Related]
9. Purification of Shiga toxin and Shiga-like toxins I and II by receptor analog affinity chromatography with immobilized P1 glycoprotein and production of cross-reactive monoclonal antibodies.
Donohue-Rolfe A; Acheson DW; Kane AV; Keusch GT
Infect Immun; 1989 Dec; 57(12):3888-93. PubMed ID: 2807552
[TBL] [Abstract][Full Text] [Related]
10. In vivo formation of hybrid toxins comprising Shiga toxin and the Shiga-like toxins and role of the B subunit in localization and cytotoxic activity.
Weinstein DL; Jackson MP; Perera LP; Holmes RK; O'Brien AD
Infect Immun; 1989 Dec; 57(12):3743-50. PubMed ID: 2807546
[TBL] [Abstract][Full Text] [Related]
11. Pathogenesis of shigella diarrhea. XI. Isolation of a shigella toxin-binding glycolipid from rabbit jejunum and HeLa cells and its identification as globotriaosylceramide.
Jacewicz M; Clausen H; Nudelman E; Donohue-Rolfe A; Keusch GT
J Exp Med; 1986 Jun; 163(6):1391-404. PubMed ID: 3519828
[TBL] [Abstract][Full Text] [Related]
12. Activation of Shiga-like toxins by mouse and human intestinal mucus correlates with virulence of enterohemorrhagic Escherichia coli O91:H21 isolates in orally infected, streptomycin-treated mice.
Melton-Celsa AR; Darnell SC; O'Brien AD
Infect Immun; 1996 May; 64(5):1569-76. PubMed ID: 8613362
[TBL] [Abstract][Full Text] [Related]
13. Comparative toxicity and virulence of Escherichia coli clones expressing variant and chimeric Shiga-like toxin type II operons.
Paton AW; Bourne AJ; Manning PA; Paton JC
Infect Immun; 1995 Jul; 63(7):2450-8. PubMed ID: 7790056
[TBL] [Abstract][Full Text] [Related]
14. Identification of three amino acid residues in the B subunit of Shiga toxin and Shiga-like toxin type II that are essential for holotoxin activity.
Perera LP; Samuel JE; Holmes RK; O'Brien AD
J Bacteriol; 1991 Feb; 173(3):1151-60. PubMed ID: 1991714
[TBL] [Abstract][Full Text] [Related]
15. A mutant Shiga-like toxin IIe bound to its receptor Gb(3): structure of a group II Shiga-like toxin with altered binding specificity.
Ling H; Pannu NS; Boodhoo A; Armstrong GD; Clark CG; Brunton JL; Read RJ
Structure; 2000 Mar; 8(3):253-64. PubMed ID: 10745005
[TBL] [Abstract][Full Text] [Related]
16. Alteration of the carbohydrate binding specificity of verotoxins from Gal alpha 1-4Gal to GalNAc beta 1-3Gal alpha 1-4Gal and vice versa by site-directed mutagenesis of the binding subunit.
Tyrrell GJ; Ramotar K; Toye B; Boyd B; Lingwood CA; Brunton JL
Proc Natl Acad Sci U S A; 1992 Jan; 89(2):524-8. PubMed ID: 1731324
[TBL] [Abstract][Full Text] [Related]
17. Specific interaction of Escherichia coli O157:H7-derived Shiga-like toxin II with human renal endothelial cells.
Louise CB; Obrig TG
J Infect Dis; 1995 Nov; 172(5):1397-401. PubMed ID: 7594687
[TBL] [Abstract][Full Text] [Related]
18. Glycolipid modification of alpha 2 interferon binding. Sequence similarity between the alpha 2 interferon receptor and verotoxin (Shiga-like toxin) B-subunit.
Lingwood CA; Yiu SK
Biochem J; 1992 Apr; 283 ( Pt 1)(Pt 1):25-6. PubMed ID: 1314564
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the relative toxicities of Shiga-like toxins type I and type II for mice.
Tesh VL; Burris JA; Owens JW; Gordon VM; Wadolkowski EA; O'Brien AD; Samuel JE
Infect Immun; 1993 Aug; 61(8):3392-402. PubMed ID: 8335369
[TBL] [Abstract][Full Text] [Related]
20. Globotriaosylceramide, Gb3, is an alternative functional receptor for Shiga-like toxin 2e.
Keusch GT; Jacewicz M; Acheson DW; Donohue-Rolfe A; Kane AV; McCluer RH
Infect Immun; 1995 Mar; 63(3):1138-41. PubMed ID: 7868240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
